- Home
- ACET vs FLUX Comparison
ACET vs FLUX Comparison
Compare ACET & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- FLUX
- Stock Information
- Founded
- ACET 1947
- FLUX N/A
- Country
- ACET United States
- FLUX United States
- Employees
- ACET N/A
- FLUX N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- FLUX Industrial Machinery/Components
- Sector
- ACET Health Care
- FLUX Miscellaneous
- Exchange
- ACET Nasdaq
- FLUX Nasdaq
- Market Cap
- ACET 111.9M
- FLUX 98.5M
- IPO Year
- ACET N/A
- FLUX N/A
- Fundamental
- Price
- ACET $0.64
- FLUX $2.22
- Analyst Decision
- ACET Buy
- FLUX Strong Buy
- Analyst Count
- ACET 4
- FLUX 2
- Target Price
- ACET $8.50
- FLUX $6.00
- AVG Volume (30 Days)
- ACET 2.2M
- FLUX 1.1M
- Earning Date
- ACET 11-05-2025
- FLUX 11-13-2025
- Dividend Yield
- ACET N/A
- FLUX N/A
- EPS Growth
- ACET N/A
- FLUX N/A
- EPS
- ACET N/A
- FLUX N/A
- Revenue
- ACET N/A
- FLUX $66,434,000.00
- Revenue This Year
- ACET N/A
- FLUX $8.23
- Revenue Next Year
- ACET N/A
- FLUX $24.72
- P/E Ratio
- ACET N/A
- FLUX N/A
- Revenue Growth
- ACET N/A
- FLUX 9.22
- 52 Week Low
- ACET $0.45
- FLUX $1.15
- 52 Week High
- ACET $1.40
- FLUX $7.55
- Technical
- Relative Strength Index (RSI)
- ACET 31.44
- FLUX 34.59
- Support Level
- ACET $0.66
- FLUX $2.20
- Resistance Level
- ACET $0.71
- FLUX $2.56
- Average True Range (ATR)
- ACET 0.07
- FLUX 0.74
- MACD
- ACET -0.03
- FLUX -0.45
- Stochastic Oscillator
- ACET 7.83
- FLUX 2.67
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.